A 0 1 0 1 O
history 2 9 2 9 O
of 10 12 10 12 O
a 13 14 13 14 O
malabsorption 15 28 15 28 B-chronic_disease
syndrome 29 37 29 37 I-chronic_disease

Abnormal 0 8 38 46 O
renal 9 14 47 52 O
function 15 23 53 61 O
tests 24 29 62 67 O
, 29 30 67 68 O
defined 31 38 69 76 O
as 39 41 77 79 O
BUN 42 45 80 83 B-clinical_variable
or 46 48 84 86 O
creatinine 49 59 87 97 B-clinical_variable
> 60 61 98 99 O
1.5 61 64 99 102 B-lower_bound
ULN 65 68 103 106 I-lower_bound
for 69 72 107 110 O
age 73 76 111 114 B-age

Asthma 0 6 115 121 B-chronic_disease
or 7 9 122 124 O
other 10 15 125 130 O
condition 16 25 131 140 O
requiring 26 35 141 150 O
treatment 36 45 151 160 B-treatment
with 46 50 161 165 I-treatment
systemic 51 59 166 174 I-treatment
corticosteroids 60 75 175 190 I-treatment
within 76 82 191 197 O
the 83 86 198 201 O
past 87 91 202 206 B-upper_bound
3 92 93 207 208 I-upper_bound
months 94 100 209 215 I-upper_bound

At 0 2 216 218 O
least 3 8 219 224 O
one 9 12 225 228 B-lower_bound
parent 13 19 229 235 O
( 20 21 236 237 O
or 21 23 237 239 O
other 24 29 240 245 O
legally 30 37 246 253 O
acceptable 38 48 254 264 O
representative 49 63 265 279 O
) 63 64 279 280 O
must 65 69 281 285 O
sign 70 74 286 290 O
the 75 78 291 294 O
informed 79 87 295 303 O
consent 88 95 304 311 O
form 96 100 312 316 O
before 101 107 317 323 O
the 108 111 324 327 O
performance 112 123 328 339 O
of 124 126 340 342 O
any 127 130 343 346 O
study 131 136 347 352 O
procedures 137 147 353 363 O
, 147 148 363 364 O
but 149 152 365 368 O
both 153 157 369 373 O
parents 158 165 374 381 O
must 166 170 382 386 O
sign 171 175 387 391 O
if 176 178 392 394 O
both 179 183 395 399 O
have 184 188 400 404 O
parental 189 197 405 413 O
rights 198 204 414 420 O

CYP2C8 0 6 421 427 B-treatment
substrates 7 17 428 438 I-treatment
( 18 19 439 440 O
rosiglitazone 19 32 440 453 B-treatment
, 32 33 453 454 O
pioglitazone 34 46 455 467 B-treatment
, 46 47 467 468 O
rapaglinide 48 59 469 480 B-treatment
) 59 60 480 481 O
and 61 64 482 485 O
CYP2D6 65 71 486 492 B-treatment
substrates 72 82 493 503 I-treatment
( 83 84 504 505 O
dextromethorphan 84 100 505 521 B-treatment
, 100 101 521 522 O
thioridazine 102 114 523 535 B-treatment
) 114 115 535 536 O
should 116 122 537 543 O
be 123 125 544 546 O
avoided 126 133 547 554 O

Children 0 8 555 563 O
who 9 12 564 567 O
are 13 16 568 571 O
capable 17 24 572 579 O
of 25 27 580 582 O
providing 28 37 583 592 O
assent 38 44 593 599 O
( 45 46 600 601 O
typically 46 55 601 610 O
10 56 58 611 613 B-lower_bound
years 59 64 614 619 I-lower_bound
of 65 67 620 622 O
age 68 71 623 626 B-age
and 72 75 627 630 O
older 76 81 631 636 O
) 81 82 636 637 O
must 83 87 638 642 O
sign 88 92 643 647 O
an 93 95 648 650 O
assent 96 102 651 657 O
form 103 107 658 662 O
before 108 114 663 669 O
the 115 118 670 673 O
performance 119 130 674 685 O
of 131 133 686 688 O
any 134 137 689 692 O
study 138 143 693 698 O
procedures 144 154 699 709 O

Concurrent 0 10 710 720 B-chronic_disease
medical 11 18 721 728 I-chronic_disease
condition 19 28 729 738 I-chronic_disease
or 29 31 739 741 I-chronic_disease
disease 32 39 742 749 I-chronic_disease
other 40 45 750 755 O
than 46 50 756 760 O
21 51 53 761 763 B-chronic_disease
- 53 54 763 764 I-chronic_disease
hydroxylase 54 65 764 775 I-chronic_disease
deficiency 66 76 776 786 I-chronic_disease
that 77 81 787 791 O
may 82 85 792 795 O
interfere 86 95 796 805 O
with 96 100 806 810 O
linear 101 107 811 817 O
growth 108 114 818 824 O
or 115 117 825 827 O
that 118 122 828 832 O
requires 123 131 833 841 O
concomitant 132 143 842 853 B-treatment
therapy 144 151 854 861 I-treatment
that 152 156 862 866 O
is 157 159 867 869 O
likely 160 166 870 876 O
to 167 169 877 879 O
interfere 170 179 880 889 O
with 180 184 890 894 O
study 185 190 895 900 O
procedures 191 201 901 911 O
or 202 204 912 914 O
results 205 212 915 922 O

Confirmed 0 9 923 932 O
classic 10 17 933 940 B-chronic_disease
21 18 20 941 943 I-chronic_disease
- 20 21 943 944 I-chronic_disease
hydroxylase 21 32 944 955 I-chronic_disease
deficiency 33 43 956 966 I-chronic_disease
evident 44 51 967 974 O
by 52 54 975 977 O
genotype 55 63 978 986 O
groups 64 70 987 993 O
A 71 72 994 995 O
, 72 73 995 996 O
A1 74 76 997 999 O
or 77 79 1000 1002 O
B 80 81 1003 1004 O
or 82 84 1005 1007 O
clinical 85 93 1008 1016 O
course 94 100 1017 1023 O
( 101 102 1024 1025 O
e.g. 102 106 1025 1029 O
, 106 107 1029 1030 O
adrenal 108 115 1031 1038 O
crisis 116 122 1039 1045 O
with 123 127 1046 1050 O
documented 128 138 1051 1061 O
hyperkalemia 139 151 1062 1074 B-chronic_disease
and 152 155 1075 1078 O
hyponatremia 156 168 1079 1091 B-chronic_disease
, 168 169 1091 1092 O
at 170 172 1093 1095 O
diagnosis 173 182 1096 1105 O
or 183 185 1106 1108 O
during 186 192 1109 1115 O
a 193 194 1116 1117 O
later 195 200 1118 1123 O
evaluation 201 211 1124 1134 O
; 211 212 1134 1135 O
ambiguous 213 222 1136 1145 O
genitalia 223 232 1146 1155 O
in 233 235 1156 1158 O
females 236 243 1159 1166 B-gender
) 243 244 1166 1167 O

Current 0 7 1168 1175 O
or 8 10 1176 1178 O
history 11 18 1179 1186 O
of 19 21 1187 1189 O
hepatitis 22 31 1190 1199 B-chronic_disease
from 32 36 1200 1204 O
any 37 40 1205 1208 O
etiology 41 49 1209 1217 O
, 49 50 1217 1218 O
including 51 60 1219 1228 O
history 61 68 1229 1236 O
of 69 71 1237 1239 O
active 72 78 1240 1246 O
viral 79 84 1247 1252 O
hepatitis 85 94 1253 1262 B-chronic_disease
A 95 96 1263 1264 I-chronic_disease
, 96 97 1264 1265 I-chronic_disease
B 98 99 1266 1267 I-chronic_disease
, 99 100 1267 1268 I-chronic_disease
or 101 103 1269 1271 I-chronic_disease
C 104 105 1272 1273 I-chronic_disease

Evidence 0 8 1274 1282 O
of 9 11 1283 1285 O
active 12 18 1286 1292 O
malignancy 19 29 1293 1303 B-cancer

Evidence 0 8 1304 1312 O
of 9 11 1313 1315 O
central 12 19 1316 1323 O
puberty 20 27 1324 1331 O
: 27 28 1331 1332 O
Tanner 29 35 1333 1339 O
Stage 36 41 1340 1345 O
> 42 43 1346 1347 O
2 43 44 1347 1348 B-lower_bound
for 45 48 1349 1352 O
breast 49 55 1353 1359 B-clinical_variable
development 56 67 1360 1371 I-clinical_variable
in 68 70 1372 1374 O
girls 71 76 1375 1380 B-gender
or 77 79 1381 1383 O
testicular 80 90 1384 1394 B-clinical_variable
volume 91 97 1395 1401 I-clinical_variable
> 98 99 1402 1403 O
4 99 100 1403 1404 B-lower_bound
mL 101 103 1405 1407 I-lower_bound
in 104 106 1408 1410 O
boys 107 111 1411 1415 B-gender
, 111 112 1415 1416 O
or 113 115 1417 1419 O
random 116 122 1420 1426 B-clinical_variable
LH 123 125 1427 1429 I-clinical_variable
> 126 127 1430 1431 O
0.3 127 130 1431 1434 B-lower_bound
mIU 131 134 1435 1438 I-lower_bound
/ 134 135 1438 1439 I-lower_bound
mL 135 137 1439 1441 I-lower_bound

Has 0 3 1442 1445 O
received 4 12 1446 1454 O
an 13 15 1455 1457 O
investigational 16 31 1458 1473 B-treatment
drug 32 36 1474 1478 I-treatment
within 37 43 1479 1485 O
4 44 45 1486 1487 B-upper_bound
weeks 46 51 1488 1493 I-upper_bound
of 52 54 1494 1496 O
the 55 58 1497 1500 O
planned 59 66 1501 1508 O
first 67 72 1509 1514 O
dose 73 77 1515 1519 O
of 78 80 1520 1522 O
study 81 86 1523 1528 B-treatment
drug 87 91 1529 1533 I-treatment
or 92 94 1534 1536 O
is 95 97 1537 1539 O
currently 98 107 1540 1549 O
enrolled 108 116 1550 1558 O
in 117 119 1559 1561 O
an 120 122 1562 1564 O
investigational 123 138 1565 1580 B-treatment
interventional 139 153 1581 1595 I-treatment
study 154 159 1596 1601 I-treatment

Known 0 5 1602 1607 O
allergies 6 15 1608 1617 O
, 15 16 1617 1618 O
hypersensitivity 17 33 1619 1635 O
, 33 34 1635 1636 O
or 35 37 1637 1639 O
intolerance 38 49 1640 1651 O
to 50 52 1652 1654 O
abiraterone 53 64 1655 1666 B-allergy_name
acetate 65 72 1667 1674 I-allergy_name
or 73 75 1675 1677 O
its 76 79 1678 1681 O
excipients 80 90 1682 1692 O
( 91 92 1693 1694 O
refer 92 97 1694 1699 O
to 98 100 1700 1702 O
United 101 107 1703 1709 O
States 108 114 1710 1716 O
Prescribing 115 126 1717 1728 O
Information 127 138 1729 1740 O
) 138 139 1740 1741 O

Morning 0 7 1742 1749 O
serum 8 13 1750 1755 B-clinical_variable
androstenedione 14 29 1756 1771 I-clinical_variable
concentrations 30 44 1772 1786 I-clinical_variable
> 45 46 1787 1788 O
1.5 46 49 1788 1791 B-lower_bound
x 50 51 1792 1793 I-lower_bound
ULN 52 55 1794 1797 I-lower_bound
after 56 61 1798 1803 B-upper_bound
7 62 63 1804 1805 I-upper_bound
days 64 68 1806 1810 I-upper_bound
of 69 71 1811 1813 O
dosing 72 78 1814 1820 O
with 79 83 1821 1825 O
doses 84 89 1826 1831 O
of 90 92 1832 1834 O
hydrocortisone 93 107 1835 1849 B-treatment
required 108 116 1850 1858 O
for 117 120 1859 1862 O
physiologic 121 132 1863 1874 O
replacement 133 144 1875 1886 O

Patients 0 8 1887 1895 O
with 9 13 1896 1900 O
baseline 14 22 1901 1909 O
hepatic 23 30 1910 1917 B-chronic_disease
impairment 31 41 1918 1928 I-chronic_disease
are 42 45 1929 1932 O
excluded 46 54 1933 1941 O
from 55 59 1942 1946 O
this 60 64 1947 1951 O
trial 65 70 1952 1957 O

Pre 0 3 1958 1961 O
- 3 4 1961 1962 O
pubescent 4 13 1962 1971 O
girls 14 19 1972 1977 B-gender

Presence 0 8 1978 1986 O
or 9 11 1987 1989 O
history 12 19 1990 1997 O
of 20 22 1998 2000 O
cataracts 23 32 2001 2010 B-chronic_disease

Requirement 0 11 2011 2022 O
for 12 15 2023 2026 O
standard 16 24 2027 2035 O
of 25 27 2036 2038 O
care 28 32 2039 2043 O
fludrocortisone 33 48 2044 2059 B-treatment
( 49 50 2060 2061 O
any 50 53 2061 2064 O
dose 54 58 2065 2069 O
) 58 59 2069 2070 O
and 60 63 2071 2074 O
â‰¥10 64 67 2075 2078 O
mg 68 70 2079 2081 I-lower_bound
/ 70 71 2081 2082 I-lower_bound
m2 71 73 2082 2084 I-lower_bound
/ 73 74 2084 2085 I-lower_bound
day 74 77 2085 2088 I-lower_bound
of 78 80 2089 2091 O
hydrocortisone 81 95 2092 2106 B-treatment
for 96 99 2107 2110 O
at 100 102 2111 2113 O
least 103 108 2114 2119 O
1 109 110 2120 2121 B-lower_bound
month 111 116 2122 2127 I-lower_bound
prior 117 122 2128 2133 I-lower_bound
to 123 125 2134 2136 O
the 126 129 2137 2140 O
study 130 135 2141 2146 O
consent 136 143 2147 2154 O

Serious 0 7 2155 2162 O
or 8 10 2163 2165 O
uncontrolled 11 23 2166 2178 O
co 24 26 2179 2181 O
- 26 27 2181 2182 O
existent 27 35 2182 2190 O
disease 36 43 2191 2198 O
, 43 44 2198 2199 O
including 45 54 2200 2209 O
active 55 61 2210 2216 B-chronic_disease
or 62 64 2217 2219 O
uncontrolled 65 77 2220 2232 B-chronic_disease
infection 78 87 2233 2242 I-chronic_disease

Significant 0 11 2243 2254 O
anemia 12 18 2255 2261 B-chronic_disease
( 19 20 2262 2263 O
hemoglobin 20 30 2263 2273 B-clinical_variable
< 31 32 2274 2275 O
12 33 35 2276 2278 B-upper_bound
g 36 37 2279 2280 I-upper_bound
/ 37 38 2280 2281 I-upper_bound
dl 38 40 2281 2283 I-upper_bound
) 40 41 2283 2284 O

Treatment 0 9 2285 2294 B-treatment
with 10 14 2295 2299 O
growth 15 21 2300 2306 O
hormone 22 29 2307 2314 O
at 30 32 2315 2317 O
enrollment 33 43 2318 2328 O
or 44 46 2329 2331 O
during 47 53 2332 2338 O
the 54 57 2339 2342 O
course 58 64 2343 2349 O
of 65 67 2350 2352 O
the 68 71 2353 2356 O
study 72 77 2357 2362 O

Treatment 0 9 2363 2372 B-treatment
with 10 14 2373 2377 I-treatment
medications 15 26 2378 2389 I-treatment
to 27 29 2390 2392 O
affect 30 36 2393 2399 O
puberty 37 44 2400 2407 O
or 45 47 2408 2410 O
synthesis 48 57 2411 2420 O
of 58 60 2421 2423 O
sex 61 64 2424 2427 B-treatment
steroids 65 73 2428 2436 I-treatment
, 73 74 2436 2437 O
including 75 84 2438 2447 O
gonadotropin 85 97 2448 2460 B-treatment
releasing 98 107 2461 2470 I-treatment
hormone 108 115 2471 2478 I-treatment
agonists 116 124 2479 2487 I-treatment
, 124 125 2487 2488 O
aromatase 126 135 2489 2498 B-treatment
inhibitors 136 146 2499 2509 I-treatment
, 146 147 2509 2510 O
or 148 150 2511 2513 O
androgen 151 159 2514 2522 B-treatment
receptor 160 168 2523 2531 I-treatment
blockers 169 177 2532 2540 I-treatment
( 178 179 2541 2542 O
e.g. 179 183 2542 2546 O
, 183 184 2546 2547 O
flutamide 185 194 2548 2557 B-treatment
, 194 195 2557 2558 O
spironolactone 196 210 2559 2573 B-treatment
) 210 211 2573 2574 O

Treatment 0 9 2575 2584 B-treatment
with 10 14 2585 2589 I-treatment
potentially 15 26 2590 2601 I-treatment
hepatotoxic 27 38 2602 2613 I-treatment
medications 39 50 2614 2625 I-treatment
( 51 52 2626 2627 I-treatment
statins 52 59 2627 2634 I-treatment
) 59 60 2634 2635 I-treatment
; 60 61 2635 2636 O
strong 62 68 2637 2643 B-treatment
inhibitors 69 79 2644 2654 I-treatment
of 80 82 2655 2657 I-treatment
CYP3A4 83 89 2658 2664 I-treatment
( 90 91 2665 2666 O
ketoconazole 91 103 2666 2678 B-treatment
, 103 104 2678 2679 O
itraconazole 105 117 2680 2692 B-treatment
, 117 118 2692 2693 O
clarithromycin 119 133 2694 2708 B-treatment
, 133 134 2708 2709 O
atazanavir 135 145 2710 2720 B-treatment
, 145 146 2720 2721 O
nefazodone 147 157 2722 2732 B-treatment
, 157 158 2732 2733 O
saquinavir 159 169 2734 2744 B-treatment
, 169 170 2744 2745 O
telithromycin 171 184 2746 2759 B-treatment
, 184 185 2759 2760 O
ritonavir 186 195 2761 2770 B-treatment
, 195 196 2770 2771 O
indinavir 197 206 2772 2781 B-treatment
, 206 207 2781 2782 O
nelfinavir 208 218 2783 2793 B-treatment
, 218 219 2793 2794 O
voriconazole 220 232 2795 2807 B-treatment
) 232 233 2807 2808 O
, 233 234 2808 2809 O
or 235 237 2810 2812 O
CYP3A4 238 244 2813 2819 B-treatment
inducers 245 253 2820 2828 I-treatment
( 254 255 2829 2830 O
e.g. 255 259 2830 2834 O
, 259 260 2834 2835 O
phenytoin 261 270 2836 2845 B-treatment
, 270 271 2845 2846 O
carbamazepine 272 285 2847 2860 B-treatment
, 285 286 2860 2861 O
rifampin 287 295 2862 2870 B-treatment
, 295 296 2870 2871 O
rifabutin 297 306 2872 2881 B-treatment
, 306 307 2881 2882 O
rifapentine 308 319 2883 2894 B-treatment
, 319 320 2894 2895 O
phenobarbital 321 334 2896 2909 B-treatment
) 334 335 2909 2910 O

age 0 3 2911 2914 B-age
2 4 5 2915 2916 B-lower_bound
years 6 11 2917 2922 I-lower_bound
[ 12 13 2923 2924 O
12 13 15 2924 2926 O
kg 16 18 2927 2929 O
minimum 19 26 2930 2937 O
] 26 27 2937 2938 O
to 28 30 2939 2941 O
8 31 32 2942 2943 B-upper_bound
years 33 38 2944 2949 I-upper_bound
inclusive 39 48 2950 2959 O
; 48 49 2959 2960 O
skeletal 50 58 2961 2969 O
age 59 62 2970 2973 O
< 63 64 2974 2975 O
10 64 66 2975 2977 B-upper_bound
years 67 72 2978 2983 I-upper_bound

age 0 3 2984 2987 B-age
2 4 5 2988 2989 B-lower_bound
years 6 11 2990 2995 I-lower_bound
[ 12 13 2996 2997 O
12 13 15 2997 2999 O
kg 16 18 3000 3002 O
] 18 19 3002 3003 O
to 20 22 3004 3006 O
9 23 24 3007 3008 B-upper_bound
years 25 30 3009 3014 I-upper_bound
inclusive 31 40 3015 3024 O
; 40 41 3024 3025 O
skeletal 42 50 3026 3034 O
age 51 54 3035 3038 O
< 55 56 3039 3040 O
11 56 58 3040 3042 B-upper_bound
years 59 64 3043 3048 I-upper_bound

boys 0 4 3049 3053 B-gender

